AstraZeneca PLC closed 23.51% short of its 52-week high of £133.88, which the company achieved on September 3rd.

DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...

AstraZeneca PLC closed 24.31% short of its 52-week high of £133.88, which the company reached on September 3rd.

A day of expert panels and prestigious honours for the UK's most impactful health innovations LONDON, May 8, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated ...

Ousia Pharma logo Omega Funds Logo . Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplas ...

Richmond American Homes of Florida, LP, a subsidiary of M.D.C. Holdings, Inc., is pleased to announce the Grand Opening of ...

AstraZeneca CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...

London: British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said ...

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S.

British pharmaceutical giant AstraZeneca reported a rise in first-quarter profit on Tuesday, driven by strong sales growth in ...